Celularity Dirección

Dirección controles de criterios 1/4

El CEO de Celularity's es Bob Hariri , nombrado en Jul 2021, tiene una permanencia de 2.75 años. compensación anual total es $5.24M, compuesta por 22.9% salario y 77.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 13.07% de las acciones de la empresa, por valor de $9.14M. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 2.8 años, respectivamente.

Información clave

Bob Hariri

Chief Executive Officer (CEO)

US$5.2m

Compensación total

Porcentaje del salario del CEO	22.9%
Permanencia del CEO	2.8yrs
Participación del CEO	13.1%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	2.8yrs

Actualizaciones recientes de la dirección

Recent updates

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

Feb 14

News Flash: Analysts Just Made A Massive Upgrade To Their Celularity Inc. (NASDAQ:CELU) Forecasts

Dec 14

Celularity: Celgene Spin-Off Developing Allogeneic Therapies

Sep 06

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bob Hariri en comparación con los beneficios de Celularity?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2023	n/a	n/a	-US$181m
Jun 30 2023	n/a	n/a	-US$83m
Mar 31 2023	n/a	n/a	US$13m
Dec 31 2022	US$5m	US$1m	US$14m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	US$31m
Mar 31 2022	n/a	n/a	-US$81m
Dec 31 2021	US$22m	US$1m	-US$100m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$188m
Mar 31 2021	n/a	n/a	-US$260m
Dec 31 2020	US$3m	US$1m	-US$208m

Compensación vs. Mercado: La compensación total de Bob($USD5.24M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Bob ha sido consistente con los resultados de la empresa en el último año.

CEO

Bob Hariri (64 yo)

2.8yrs

Permanencia

US$5,242,529

Compensación

Dr. Robert Joseph Hariri, also known as Bob, M.D., Ph.D. is a Co-Founder of Human Longevity, Inc. and serves as President of Human Longevity Cellular Therapeutics. He serves as Medical Advisor at Beyond Im...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Hariri	Founder	2.8yrs	US$5.24m	13.07% $ 8.6m
David Beers	Chief Financial Officer	2.8yrs	US$1.71m	0.034% $ 22.4k
John Haines	Senior EVP	1.5yrs	US$2.50m	0.0049% $ 3.2k
Ramji Krishnan	Chief Technology Officer	less than a year	sin datos	sin datos
Carlos Ramirez	SVP of Investor Relations	no data	sin datos	sin datos
Kyle Fletcher	Executive VP	1.8yrs	sin datos	0.0034% $ 2.2k
Stephen Brigido	President of Degenerative Diseases	2.8yrs	sin datos	0.0025% $ 1.7k
Adrian Kilcoyne	Executive VP	1.5yrs	sin datos	0.52% $ 340.0k
Sharmila Koppisetti	Senior Vice President of Clinical Dev. Immunology & Drug Safety	2.3yrs	sin datos	sin datos
Tim Wilk	Senior Vice President of Technical Operations	less than a year	sin datos	sin datos
David Lemus	Treasurer	no data	sin datos	sin datos
Timothy Smith	Secretary	no data	sin datos	sin datos

1.8yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CELU no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Hariri	Founder	2.8yrs	US$5.24m	13.07% $ 8.6m
Diane Parks	Independent Director	1.8yrs	US$627.68k	0.017% $ 11.0k
Louis Weiner	Member of Scientific Advisory Board	2.3yrs	sin datos	sin datos
Dean Kehler	Independent Director	6.3yrs	US$373.00k	0.85% $ 559.1k
Peter Diamandis	Independent Director	2.8yrs	US$353.50k	0.51% $ 335.5k
Marc Mazur	Independent Director	4.9yrs	US$371.00k	0.039% $ 25.8k
Geoffrey Shiu Ling	Director	less than a year	sin datos	sin datos
Darren Sigal	Co-Chairman of Scientific Advisory Board	no data	sin datos	sin datos

2.8yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de CELU no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Celularity Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors

Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees

Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

High number of new and inexperienced directors

Independent Director exercised options to buy US$822k worth of stock.

Recent updates

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Inc. announced delayed annual 10-K filing

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

High number of new and inexperienced directors

Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Genting Berhad Engages in Discussions with Celularity Inc

Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Inc. announced delayed 10-Q filing

Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees

Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Celularity Inc. to Present Data from a New Product Technology in Development for Orthopedic Applications at 7th International Conference on Orthopedics

New major risk - Share price stability

Celularity Inc. Announces Results from Exploratory Analysis of Phase 1 Data Evaluating Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn's Disease

Celularity Inc. announced delayed 10-Q filing

Price target decreased by 24% to US$8.63

Consensus revenue estimates decrease by 36%, EPS upgraded

Independent Director exercised options to buy US$822k worth of stock.

Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (Ctw)

Celularity Inc. Announces the Suspends of Robert Hariri as Chairman

Price target decreased by 12% to US$9.50

Celularity Inc. Announces in A Preclinical in Vivo Study of Placental Extracellular Matrix

Celularity Inc.'s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn's Disease in Phase 1, Phase 1b/2a and Phase 1b Studies

Celularity Inc. Appoints Paul Graves as Chief Communications Officer

Consensus forecasts updated

Celularity Inc. Announces Halal Certification of Its Advanced Cellular Therapeutics, Biomaterial Products and Business Model

Founder recently bought US$70k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$0.034 (vs US$0.47 in 3Q 2021)

Imugene’s on CARlytics Combination with Celularity’s Placental-derived off-the-shelf Allogeneic CYCART-19 T Cells Preclinical Data Presented at SITC Annual Meeting

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Celularity Promotes Two Executives in Executive Leadership Team

Celularity Appoints Adrian Kilcoyne as Executive Vice President, Chief Medical Officer and Head of Global Affairs, Patient Safety and Patient Affairs

Celularity appoints Adrian Kilcoyne as chief medical officer

Celularity Inc. Publishes New Data in Frontiers in Immunology Demonstrating Placental-Derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-Infected Cells in Vitro

Celularity Inc. Announces Resignation of Andrew L. Pecora, M.D., F.A.C.P., as Company’s President Effective as of August 31, 2022

Celularity falls after announcing fund raising deal

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Celularity falls 10% on deal for $150M common stock offering

Founder exercised options to buy US$343k worth of stock.

Price target decreased to US$10.60

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Celularity Inc. Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers

Celularity Inc. Announces the Resignation of Andrew L. Pecora as President, Effective from August 31, 2022

Price target increased to US$11.80

Celularity Inc. Announces Board Changes

Celularity Inc. Appoints Diane Parks to Board of Directors

Celularity Inc. announced that it has received $30.000007 million in funding

Consensus estimates of losses per share improve by 34%

Celularity Inc. announced that it expects to receive $30.000007 million in funding

First quarter 2022 earnings: Revenues exceed analyst expectations

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

Celularity Inc. Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

Consensus forecasts updated

Celularity Inc. Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition